Definium provides DT120 ODT clinical updates; MDD/GAD readouts in 2H 2026, expansion into PTSD

Definium Therapeutics, Inc.

MDD Emerge trial topline data on track for late 2Q 2026; 149 participants randomized 1:1 to DT120 100 µg or placebo.
GAD Voyage trial fully enrolled at 214 participants; topline data expected early 3Q 2026.
GAD Panorama sample size re-estimated to 200; screening closed, topline readout now late 3Q 2026 (previously 2H 2026).
PTSD program expanded with Phase 3 Haven study (~200 pts) initiating in 2027; primary endpoint CAPS-5 at Week 8.
Company presented commercial strategy for DT120 ODT as a potential multi-billion-dollar opportunity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.